Page 235 of 440: studies 2,341 to 2,350 of 4,392, newest first. Back to the psilocybin overview
March 1, 2023 David Nutt, David Castle 4 citations
Abstract There is substantial contemporary interest in psychedelic agents as medicines for maladies of the mind. This follows research in the 1950s and 1960s exploring the use of LSD and other psychedelics to treat a range of psychiatric illnesses as well as addictions. This research was shut down after prohibition of these drugs; however, the last decade has seen a major renewal of interest in...
Journal of Bioethical Inquiry March 1, 2023 Lauren S Otterman 9 citations
Eating disorders are debilitating diseases that have twin impacts on the body and mind and are associated with a number of physiological and psychological comorbidities (Blinder, Cumella, and Sanathara 2006; Casiero and Frishman 2006), including increased suicide risk (Arcelus et al. 2011; Lipson and Sonneville 2020). In addition, eating disorders are growing in prevalence (Gilmache et al....
Psychiatric News February 16, 2023 Terri D'Arrigo
Bills that would decriminalize the use of psychedelics are popping up faster than magic mushrooms, but the field of psychedelics research has yet to yield supporting evidence about their safety and efficacy. Legislative reform regarding psychedelics is gaining ground, a study in JAMA Psychiatry has found. From January 1, 2019, to September 28, 2022, 25 states considered 74 bills that proposed...
Frontiers in Psychiatry February 10, 2023 Muhammad Ishrat Husain, Nicole Ledwos, Elise Fellows et al. 47 citations
Introduction Current treatment options for major depressive disorder (MDD) have limited efficacy and are associated with adverse effects. Recent studies investigating the antidepressant effect of serotonergic psychedelics—also known as classic psychedelics—have promising preliminary results with large effect sizes. In this context, we conducted a review of the putative neurobiological...
Toxics February 3, 2023 Luis Alberto Henríquez-Hernández, Jaime Rojas-Hernández, Domingo Jesús Quintana Hernández et al. 21 citations
Psychedelics are experiencing a strong renaissance and will soon be incorporated into clinical practice. However, there is uncertainty about how much harm they can cause at what doses. This review aimed to collect information on the health-hazardous doses of psychedelic substances, to be aware of the risks to which patients may be subjected. We focused on ergolamines, simple tryptamines, and...
Journal of Affective Disorders February 1, 2023 Kwonmok Ko, Emma I Kopra, Anthony J. Cleare et al. 144 citations
Psychedelic therapy shows promise for Major Depressive Disorder, especially when treatment-resistant, as well as life-threatening illness distress. The objective of this systematic review, inclusive of meta-analysis, is to examine recent clinical research on the therapeutic effects of classic psychedelics on depressive symptoms. Fourteen psychedelic therapy studies, utilising psilocybin,...
ACS Chemical Neuroscience February 1, 2023 Lindsay P. Cameron, Seona D Patel, Maxemiliano V. Vargas et al. 113 citations
Psychedelic compounds have displayed antidepressant potential in both humans and rodents. Despite their promise, psychedelics can induce undesired effects that pose safety concerns and limit their clinical scalability. The rational development of optimized psychedelic-related medicines will require a full mechanistic understanding of how these molecules produce therapeutic effects. While the...
Frontiers in Neuroscience January 31, 2023 Daniel Perkins, Kimberley Day, Jerome Sarris et al. 27 citations
Ayahuasca is a psychoactive Amazonian plant brew. It is usually made from the Banisteriopsis caapi vine (Spruce ex Griseb. Morton, Malpighiaceae), which contains three primary harmala alkaloids, along with the leaves of Psychotria viridis (Ruiz et Pavon, Rubiaceae) in which the potent psychedelic dimethyltryptamine (DMT) is found. DMT-harmaloid concoctions have gained popularity in recent...
Advances in Research January 30, 2023 Jennings Hernandez
Roughly over 700 million individuals suffer from a mental illness globally. In the United States alone, over 45 million individuals are afflicted with a mental disorder at any given point in their lives. It is because of this that new methods of current therapies should be considered. To date, major depression disorder (MAD), anxiety, and post-traumatic stress disorder (PTSD) are treated with...
Journal of Psychoactive Drugs January 22, 2023 Fiona Low, Mitch Earleywine 3 citations
Patient-perceived treatment credibility is linked to important outcome measures including symptom reduction, therapeutic alliance, patient satisfaction, and attrition rates. However, few studies have tested strategies to enhance treatment credibility. The present study investigates the effect of brief, written educational materials and the use of an image induction prime on perceptions of...